Adipose stem cell-derived nanovesicles for cardioprotection: production and identification of therapeutic components.
Huang C., Chng WH., Neupane YR., Lai Y., Cui W., Yang M.
Animal Study on Cardiovascular Disease, published in J Control Release (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- J Control Release (2025)
- Country
- Netherlands
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 40582645
- DOI
- 10.1016/j.jconrel.2025.113989
- Citations
- 5
Abstract (original English)
Extracellular vesicles (EVs) derived from stem cells have shown therapeutic benefits in myocardial injury. However, the challenges in their large-scale production and elusive molecular mechanisms underlying their therapeutic effects have been hindering their clinical translation. Here, in a mouse model of myocardial ischemia-reperfusion, EVs isolated from human adipose tissue and EV-like nanovesicles fabricated with adipose stem cells (ADSCs) via a membrane extrusion approach, termed ADSC-derived nanovesicles (ADSC-CDNs), exhibited comparable cardioprotective effects, validating this EV-mimetic strategy. CDNs generated from the human monocytic cell line U937 similarly conferred protection, whereas those from HEK293 cells did not, highlighting the importance of cell source for therapeutic efficacy. microRNA profiling identified miR-24-3p as a predominant therapeutic cargo in ADSC-EVs and ADSC-CDNs. This microRNA upregulates the cytoprotective transcription factor Nrf2, thereby suppressing cardiomyocyte apoptosis. Functional assays also confirmed that miR-24-3p was a key component mediating the cardioprotective effects of those nanovesicles. Importantly, this study introduces a cell-source-dependent, scalable, and high-yield production platform for ADSC-CDNs that preserves molecular cargo profile of the parent cells, ensuring consistent therapeutic content. This EV-mimetic platfo
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level ASystematic ReviewEurope PMC
Factor XII-A New Therapeutic Target? A Systematic Review
Systematic Review on Cardiovascular Disease, Neuroinflammation, published in Int J Mol Sci (2026) — summary generated from the PubMed abstract.
- 2026
Int J Mol Sci1 citations - Level AMeta-analysisEurope PMC
Can cell-based therapies bridge the gap between research and reality in the treatment of myocarditis? A systematic review and meta-analysis
Meta-analysis on Cardiovascular Disease, published in Regen Ther (2026) — summary generated from the PubMed abstract.
- 2026
Regen Ther - Level AMeta-analysisEurope PMC
Efficacy and safety of stem cell therapy for myocardial infarction and heart failure: an updated systematic review and meta-analysis of randomized controlled trials
Meta-analysis with a reported sample of 3345 on Cardiovascular Disease, Stroke Research, published in Syst Rev (2026) — summary generated from the PubMed abstract.
- 2026
- n = 3345
Syst Rev - Level AMeta-analysisEurope PMC
Orally derived mesenchymal stem cells in the treatment of vascular diseases: a systematic review and meta-analysis
Meta-analysis on Cardiovascular Disease, published in Sci Rep (2026) — summary generated from the PubMed abstract.
- 2026
Sci Rep - Level ASystematic ReviewEurope PMC
From Preservation to Repair: A Systematic Review of Therapeutic Organ Rehabilitation During Normothermic Ex Vivo Machine Perfusion
Systematic Review with a reported sample of 12 on Cardiovascular Disease, Immune Modulation, published in Transplant Direct (2026) — summary generated from the PubMed abstract.
- 2026
- n = 12
Transplant Direct - Level AMeta-analysisEurope PMC
Safety and Efficacy of Transendocardial Stem Cells Therapy in Chronic Ischemic Heart Failure: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Meta-analysis on Cardiovascular Disease, Stroke Research, published in Curr Cardiol Rev (2025) — summary generated from the PubMed abstract.
- 2025
Curr Cardiol Rev